Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Papillex Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This action is assigned to 1 distinct examiner. The singular nature of the pending matter indicates a focused prosecution phase for the company's current patent interests.
The busiest examiner for this portfolio is DEKARSKE, MADELINE MCGUIRE, who is responsible for 1 pending office action. The involvement of 1 distinct art unit further highlights the concentrated administrative status of the pending application. This single point of contact simplifies the tracking of the company's current patent office activity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DEKARSKE, MADELINE MCGUIRE | 1 | 20.0% | +50.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18677013 | COMPOSITIONS FOR MANAGEMENT OF HPV (HUMAN PAPILLOMA VIRUS) INFECTIONS | DEKARSKE, MADELINE MCGUIRE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18677013 | COMPOSITIONS FOR MANAGEMENT OF HPV (HUMAN PAPILLOMA VIRUS) INFECTIONS | DEKARSKE, MADELINE MCGUIRE | — |
| Art Unit | Apps |
|---|---|
| 1622 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18677013 | COMPOSITIONS FOR MANAGEMENT OF HPV (HUMAN PAPILLOMA VIRUS) INFECTIONS | DEKARSKE, MADELINE MCGUIRE | 1622 | §103 | Non-Final OA | — | Pending | May 29, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialPapillex Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Madeline Mcguire Dekarske has the most, with 1 of Papillex Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
